Nachrichten zur Hims & Hers Health Inc. Aktie

FDA Peptide Ruling: Recent regulatory developments have dominated conversations around Hims & Hers Health, with an FDA advisory committee vote…

Hims & Hers Health Inc. is in the spotlight Friday after an FDA advisory panel voted Thursday to recommend four…

The latest FDA advisory panel vote on broader peptide compounding access, including BPC-157 and related compounds, has pushed Hims &…

A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The…

Hims & Hers shares crash as FDA panel votes against emideltide’s addition to the 503A Bulks List. Here’s what the…

Hims & Hers shares crash as FDA panel votes against emideltide’s addition to the 503A Bulks List. Here’s what the…

Hims & Hers Health stock has delivered a very large 5 year gain, yet the latest valuation work suggests the…

Hims & Hers Health Inc (HIMS) Analyst Rating Update On July 24, 2026, Truist Securities announced it…

On July 24, 2026, Hims & Hers Health (HIMS) experienced a decline of over 11% following an unfavorable decision from…

Hims & Hers (HIMS) stock slides after an FDA advisory panel for the first time in a two-day meeting declines…

On July 24, 2026, Hims & Hers Health Inc (HIMS) experienced a notable decline in its stock price, dropping by…

Hims & Hers Health, Inc. (HIMS) is down 10.4% today. Here is some analysis on what might have caused this…

Hims & Hers stock is upgraded to "Buy" given its upside potential. Heres what investors need to know.…

Hims & Hers (HIMS) is down -10.3%, or -$3.38 to $29.36. Published first on TheFly – the ultimate source for…

What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured…

What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured…

Ich halte die Euphorie um Hims & Hers für verfrüht. Acht Ja-Stimmen gegen sechs Nein-Stimmen bei einer Enthaltung – mit…

Eine 8-zu-6-Empfehlung ist keine Zulassung. Die FDA-Berater öffnen Peptide wie BPC-157 für die Apothekenherstellung, doch die Behörde muss erst ein…

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the…

Hims & Hers Health is in focus Friday after an FDA advisory panel on Thursday recommended adding four peptides to…

Peptide catalyst lift for Hims & Hers (NYSE:HIMS) limited by FDA review timetable - TechStock²…

Telehealth companies including Hims & Hers Health Inc. and Noom Inc. urged a panel of experts to recommend legalizing several…

Earlier in July 2026, Hims & Hers Health announced that Chief Accounting Officer and Principal Accounting Officer Irene Becklund will…

In July 2026, an FDA advisory committee recommended easing compounding restrictions on several peptides, including BPC-157, while Hims & Hers…

Hims & Hers Health has been upgraded from Hold to Buy due to its disciplined operations and strategic growth in…

Hims & Hers Health (HIMS) is back in focus after an FDA advisory panel recommended allowing broader compounding of peptide…

On July 23, 2026, Hims & Hers Health Inc (HIMS) shares rose 3.4% today, closing at $32.74. The stock has…

Hims and Hers stock gains on peptide compounding vote outlook…

Hims and Hers stock gains on peptide compounding vote outlook…

Hims & Hers Health Analyst Rating Update On July 23, 2026, Citigroup maintained a Neutral rating on…

Why is Hims & Hers Health stock rallying today?…